GU Cancers 2021 | Enfortumab vedotin in urothelial cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of the antibody-drug conjugate, enfortumab vedotin, for patients with urothelial cancer. A randomized trial showed overall improved response and survival rates in patients treated with enfortumab vedotin compared to taxane-based chemotherapy. In patient’s ineligible for front-line platinum-based therapy, enfortumab vedotin was active and tolerable, however it is essential to look out for toxicities. Patients with bone metastases also benefited from the use of enfortumab vedotin. This interview took place during the 2021 Genitourinary Cancers Symposium.